Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Psychosis: Goals of Pharmacotherapy

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...

Antipsychotic Drugs: Typical and Atypical Agents

Antipsychotic Drugs: Typical and Atypical Agents

Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...

Psychosis and Antipsychotic Drugs: Overview

Psychosis and Antipsychotic Drugs: Overview

The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic symptoms in all...

Antidepressant Drugs: MAOIs and Other Agents

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...

Antipsychotic Drugs: Therapeutic Uses and Side Effects

Antipsychotic Drugs: Therapeutic Uses and Side Effects

Antipsychotic drugs primarily block dopamine and serotonin receptors and cholinergic, adrenergic, and histaminergic receptors, thereby reducing hallucinations and delusions in conditions like schizophrenia. However, they can trigger unwanted extrapyramidal effects such as dystonias, Parkinson-like symptoms, and tardive dyskinesia.
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Doctors' reporting of mental health stigma and barriers to help-seeking.

Occupational medicine (Oxford, England)·2021

Same author

Validation of psoriasis disability index (PDI) questionnaire Sinhala version.

Archives of dermatological research·2021

Same author

Validation of Sinhala version of Psoriasis Epidemiology Screening Tool.

Clinical rheumatology·2021

Same author

Genetic association between antipsychotic induced weight gain and FTO gene in a Sri Lankan population

The Ceylon medical journal·2019

Same author

Barriers for Cataract Treatment among Elderly in Sri Lanka.

Current gerontology and geriatrics research·2019

Same author

Late-onset bipolar disorder: preliminary results from Sydney.

Acta neuropsychiatrica·2016

Same journal

Psilocybin reduces fear memory and restores neuroplasticity in the hippocampus and medial prefrontal cortex.

Journal of psychopharmacology (Oxford, England)·2026

Same journal

Classical psychedelic microdosing, mood, and cognitive function: An umbrella review with narrative synthesis.

Journal of psychopharmacology (Oxford, England)·2026

Same journal

The purpose of the psychosocial protocol in the psychedelic-assisted therapy: A scoping review.

Journal of psychopharmacology (Oxford, England)·2026

Same journal

Mitochondrial dysfunction in schizophrenia and its modulation by atypical antipsychotic drugs: A randomized controlled trial.

Journal of psychopharmacology (Oxford, England)·2026

Same journal

Effects of pimavanserin, xanomeline and highly-purified plant-derived cannabidiol on MK-801-induced behaviours in mice relevant to psychosis.

Journal of psychopharmacology (Oxford, England)·2026

Same journal

Pharmacokinetics and pharmacodynamics of orally administered S-ketamine in healthy participants.

Journal of psychopharmacology (Oxford, England)·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 25, 2026

Methods for Studying the Mechanisms of Action of Antipsychotic Drugs in Caenorhabditis elegans

Methods for Studying the Mechanisms of Action of Antipsychotic Drugs in Caenorhabditis elegans

Published on: February 4, 2014

Clozapine-associated weight loss.

R Hanwella¹, V de Silva, C Wijeratne

¹Department of Psychological Medicine, Faculty of Medicine, Colombo, Sri Lanka.

Journal of Psychopharmacology (Oxford, England)

|March 7, 2009

Summary

This summary is machine-generated.

Clozapine typically causes weight gain, but this study reports three cases of significant weight loss in patients treated with clozapine. Investigations found no other cause for this unexpected weight reduction.

More Related Videos

Using the Activity-based Anorexia Rodent Model to Study the Neurobiological Basis of Anorexia Nervosa

Using the Activity-based Anorexia Rodent Model to Study the Neurobiological Basis of Anorexia Nervosa

Published on: October 22, 2015

Related Experiment Videos

Last Updated: Jun 25, 2026

Methods for Studying the Mechanisms of Action of Antipsychotic Drugs in Caenorhabditis elegans

Methods for Studying the Mechanisms of Action of Antipsychotic Drugs in Caenorhabditis elegans

Published on: February 4, 2014

Using the Activity-based Anorexia Rodent Model to Study the Neurobiological Basis of Anorexia Nervosa

Using the Activity-based Anorexia Rodent Model to Study the Neurobiological Basis of Anorexia Nervosa

Published on: October 22, 2015

Area of Science:

Psychiatry
Pharmacology
Metabolic Medicine

Background:

Clozapine is an atypical antipsychotic medication used for treatment-resistant schizophrenia.
Weight gain is a common and significant side effect associated with clozapine treatment.
Understanding atypical adverse effects is crucial for patient management.

Observation:

Three patients treated with clozapine experienced substantial, unexplained weight loss.
Weight loss ranged from 14.4 kg to 33 kg, representing 18% to 49% of body weight.
Two of the affected patients had a history of diabetes mellitus.

Findings:

The observed weight loss was significant and not attributable to other medical conditions or lifestyle changes.
The mechanism behind clozapine-induced weight loss remains unclear.
This contrasts with the well-documented association between clozapine and weight gain.

Implications:

These cases highlight the need for vigilant monitoring of weight changes in patients on clozapine, in both directions.
Further research is required to elucidate the pathophysiology of clozapine-associated weight loss.
Clinicians should consider clozapine as a potential cause of significant weight loss in patients presenting with this symptom.